MarketPulse

MC4R agonist

2 articles
BenzingaBenzinga··Vandana Singh

Rhythm Pharma's Obesity Drug Fails Primary Trial, Pivots to Next-Gen Candidates

Rhythm Pharmaceuticals' setmelanotide fails EMANATE Phase 3 primary endpoints for rare genetic obesity, sending stock down 4.98%. Company pivots to next-generation MC4R agonists.
RYTMbiotechclinical trial failure
GlobeNewswire Inc.GlobeNewswire Inc.··Rhythm Pharmaceuticals, Inc.

Rhythm Pharma's Setmelanotide Shows 18.8% BMI Reduction in Obesity Trial

Rhythm Pharmaceuticals reports positive Phase 3 data for setmelanotide treating acquired hypothalamic obesity, with FDA decision expected March 2026.
RYTMFDA approvalrare disease